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Background: 18F-FDG PET/CT imaging is widely utilized in the clinical evaluation of patients with suspected or
documented lymphoma. The aim was to describe our cumulative experience with a multimodal 18F-FDG-directed
lymph node surgical excisional biopsy approach in patients with suspected lymphoma.
Methods: Thirteen patients (mean age 51 (±16;22–76) years), with suspected new or suspected recurrent
lymphoma suggested by 18F-FDG-avid lesions seen on prior diagnostic whole-body PET/CT imaging, were injected
IV with 18F-FDG prior to undergoing same-day diagnostic lymph node surgical excisional biopsy in the operating
room. Various 18F-FDG detection strategies were used on the day of surgery, including, (1) same-day pre-resection
patient PET/CT; (2) intraoperative gamma probe assessment; (3) clinical scanner specimen PET/CT imaging of
whole surgically excised tissue specimens; (4) specimen gamma well counts; and/or (5) same-day post-resection
patient PET/CT.
Results: Same-day 18F-FDG injection dose was 14.8 (±2.4;12.5-20.6) millicuries or 548 (±89;463–762)
megabecquerels. Sites of 18F-FDG-avid lesions were 4 inguinal, 3 cervical, 3 abdominal/retroperitoneal, 2 axillary,
and 1 gluteal region subcutaneous tissue. Same-day pre-resection patient PET/CT was performed on 6 patients.
Intraoperative gamma probe assessment was performed on 13 patients. Clinical scanner PET/CT imaging of whole
surgically excised tissue specimens was performed in 10 cases. Specimen gamma well counts were performed in 6
cases. Same-day post-resection patient PET/CT imaging was performed on 8 patients. Time from 18F-FDG injection
to same-day pre-resection patient PET/CT, intraoperative gamma probe assessment, and same-day post-resection
patient PET/CT were 76 (±8;64–84), 240 (±63;168–304), and 487 (±104;331–599) minutes, respectively. Time from
18F-FDG injection to clinical scanner PET/CT of whole surgically excised tissue specimens was 363 (±60;272–446)
minutes. Time from 18F-FDG injection to specimen gamma well counts was 591 (±96;420–689) minutes. Intraoperative
gamma probe assessment successfully identified 18F-FDG-avid lesions in 12/13 patients. Histopathologic evaluation
confirmed lymphoma in 12/13 patients and benign disease in 1/13 patients.
Conclusions: A multimodal approach to 18F-FDG-directed lymph node surgical excisional biopsy for suspected
lymphoma is technically feasible for guiding appropriate diagnostic tissue sampling of lymph nodes seen as
18F-FDG-avid lesions on diagnostic 18F-FDG PET/CT imaging.
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Diagnostic 18F-fluorodeoxyglucose (18F-FDG) positron
emission tomography/computed tomography (PET/CT)
imaging is widely utilized in the clinical assessment of
patients with lymphoma, including for initial staging,
treatment monitoring during therapy, restaging after
completion of therapy, and detection of suspected recur-
rent disease [1-13]. These various applications of diagnos-
tic 18F-FDG PET/CT imaging can dramatically influence
management/therapy recommendations for lymphoma
patients and can have the potential to positively impact
upon long-term patient outcomes.
The surgeon has continued to play an important role
in facilitating the diagnostic pathway for patients with
suspected new or suspected recurrent lymphoma, as the
findings noted on diagnostic 18F-FDG PET/CT imaging
that are considered suspicious for lymphoma frequently
require the subsequent performance of a lymph node
surgical excisional biopsy procedure for confirmation of
a definitive diagnosis [14], as well as for histopathologic,
immunophenotypic, flow cytometry, and molecular sub-
type analyses [15].
Over the last 15 years, there has been increasing inter-
est by surgeons and nuclear medicine/molecular imaging
physicians in utilizing 18F-FDG and PET/CT imaging
technology to attempt to provide real-time information
within the operative room and perioperative setting for
cancer patients [16-75]. Specifically related to our collab-
orative efforts at The Ohio State University, we have
previously investigated the use of a novel, multimodal
imaging and detection approach involving perioperative
patient and ex vivo surgical specimen 18F-FDG PET/CT
imaging in combination with intraoperative 18F-FDG
gamma probe detection [61]. In this regard, the aim of this
study was to describe our cumulative experience in pa-
tients with suspected new or suspected recurrent lymph-
oma with a multimodal approach to 18F-FDG-directed
lymph node surgical excisional biopsy for guiding appro-
priate diagnostic tissue sampling of lymph nodes that are
seen as 18F-FDG-avid lesions on prior diagnostic whole-
body 18F-FDG PET/CT imaging.
Methods
All aspects of the current retrospective analysis were ap-
proved by the Cancer Institutional Review Board (IRB)
at The Ohio State University Wexner Medical Center.
The data for the current retrospective analysis were ac-
quired from a master prospectively-maintained database
(with database inclusion dates from June 2005 to June
2012), which were generated from the combination of
several Cancer IRB-approved protocols, and which in-
volved a multimodal imaging and detection approach to
18F-FDG-directed surgery for the localization and resec-
tion of 18F-FDG-avid lesions in patients with known andsuspected malignancies. This multimodal imaging and
detection approach to 18F-FDG-directed surgery in-
cluded 166 patients who gave consent to participate in
one of the IRB-approved protocols, and a total of 157
patients who eventually were taken to the operating
room for 18F-FDG-directed surgery.
The imaging parameters of this multimodal imaging
and detection approach to 18F-FDG-directed surgery
have been previously described in significant detail else-
where [61,74]. All participating patients received a same-
day single-dose preoperative intravenous injection of
18F-FDG. All patients fasted for a minimum of 6 hours
prior to receiving their same-day single-dose preopera-
tive intravenous injection of 18F-FDG. Various 18F-FDG
detection strategies were used, including: (1) same-day
pre-resection whole body or limited field of view patient
PET/CT scan (consisting of 6 to 8 field of view PET bed
positions for whole body imaging with 2 minutes of PET
imaging per each PET bed position or consisting of 1 to
3 field of view PET bed positions for limited field of view
imaging with 2 minutes of PET imaging per each PET
bed position); (2) intraoperative gamma probe assess-
ment; (3) clinical scanner PET/CT imaging of whole sur-
gically excised tissue specimens (consisting of 1 field of
view PET bed position for 10 minutes); (4) specimen
gamma well counting; and/or (5) same-day post-resection
limited field of view patient PET/CT scan (consisting of 1
to 3 field of view PET bed positions, with 10 minutes of
PET imaging per each PET bed position). The 18F-FDG
PET/CT images were acquired on one of three clinical
diagnostic scanners: (1) Siemens Biograph 16 (Siemens,
Knoxville, Tennessee); (2) Phillips Gemini TF (Philips,
Amsterdam, Netherlands); and (3) Siemens Biograph 64
Slice mCT (Siemens, Knoxville, Tennessee). The 18F-FDG
PET/CT images were all analyzed on a Philips Extended
Brilliance Work Station (Philips, Amsterdam, Netherlands).
For each individual patient, the same-day preoperative diag-
nostic 18F-FDG PET/CT scan, the same-day postoperative
diagnostic 18F-FDG PET/CT scan, and the whole surgically
excised tissue specimen PET/CT scan were performed on
the same clinical diagnostic scanner.
All presumed 18F-FDG-avid lesions seen on diagnostic
18F-FDG PET/CT imaging were reported out with a
maximum standard uptake value (SUVmax) on each pre-
sumed 18F-FDG-avid lesion. Likewise, there was no “min-
imal set threshold value” for the SUVmax on any given
presumed 18F-FDG-avid lesion to be considered as a des-
ignation of an “abnormal” hypermetabolic 18F-FDG-avid
focus and to be reported out as “suspicious for malig-
nancy”. Rather, the determination of any given presumed
18F-FDG-avid lesion to be considered as a designation of
an “abnormal” hypermetabolic 18F-FDG-avid focus and
to be reported out as “suspicious for malignancy” was
considered more complex than simply being based upon
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and expertise/experience of the reporting nuclear medi-
cine physician.
Intraoperative gamma probe assessment was under-
taken to all 18F-FDG-avid tissue sites using various com-
binations of 6 different available gamma detection probe
systems that were synchronously or dissynchronously
available during the study period. Intraoperative gamma
probe assessment of 18F-FDG-avid tissue positivity was
determined as based utilization of the concept of the
three-sigma statistical threshold criteria. The three-
sigma statistical threshold criteria for gamma probe
positivity was previously popularized for radioimmuno-
guided surgery by Thurston [70,75-77], and the deriv-
ation of its application to 18F-FDG-avid tissue positivity
was most recently articulated by Chapman et al. [75].
The three-sigma statistical threshold criteria was calcu-
lated by taking the standard deviation derived from the
normal background tissue count rate and multiplying
that standard deviation by a factor of three, and then
adding that number to the normal background tissue
count rate [70,75-77]. Using this statistical threshold
methodology, intraoperative gamma probe assessment of
18F-FDG-avid tissue positivity was confirmed when the
count rate for the target tissue exceeded the three-sigma
statistical threshold criteria [70,75]. A fixed ratiometric
18F-FDG-avid lesion-to-background count ratio threshold
was not utilized for the determination of probe positivity.
All continuous variables were expressed as mean value
(± standard deviation; range). The software program
IBM SPSS® 21 for Windows® (SPSS, Inc., Chicago, Illi-
nois) was used for the data analysis. All mean value
comparisons for continuous variables were performed by
using the 2-tailed paired samples t-test. All categorical
variable comparisons were made using 2 x 2 contingency
tables that were analyzed by either the Pearson chi-
square test or the Fisher exact test, when appropriate. P-
values determined to be 0.05 or less were considered to
be statistically significant.
Results
There were 13 patients with either suspected new lymph-
oma (n = 2) or suspected recurrent lymphoma (n = 11)
that were available for the current analysis, as suggested by
18F-FDG-avid lesions seen on their prior diagnostic whole-
body PET/CT imaging. This included 10 females and 3
males. Their mean age was 51 (±16; range, 22–76) years.
The mean SUVmax for the hottest 18F-FDG-avid lesion
seen on their most recent prior diagnostic whole-body
PET/CT scans was 11.5 (±8.0; range, 1.7-25.6). The time of
the most recent prior diagnostic whole-body PET/CT scan
to the time of surgery was 13 (±17; range, 0–48) days.
The anatomical sites of the 18F-FDG-avid lesions were
4 inguinal/groin region sites, 3 cervical region sites, 3abdominal/retroperitoneal sites, 2 axillary region sites,
and 1 gluteal subcutaneous tissue site. These anatomical
sites of the 18F-FDG-avid lesions were clinically palpable
on physical examination in only 5 of the 13 patients.
These 13 patients were intravenously injected with
18F-FDG prior to undergoing a same-day diagnostic
lymph node surgical excisional biopsy procedure in the
operating room, with a mean same-day 18F-FDG injec-
tion dose of 14.8 (±2.4; range, 12.5-20.6) millicuries or
548 (±89; range, 463–762) megabecquerels (Table 1).
A same-day pre-resection patient PET/CT imaging
was performed on 6 patients, including 4 same-day pre-
resection whole body patient PET/CT scans and 2 same-
day pre-resection limited field of view patient PET/CT
scans. Intraoperative gamma probe assessment was per-
formed on all 13 patients. Clinical scanner specimen
PET/CT imaging of whole surgically excised tissue spec-
imens was performed in 10 cases. Specimen gamma well
counting was performed in 6 cases. A same-day post-
resection limited field of view patient PET/CT imaging
was performed on 8 patients.
As shown in Table 1, the time from 18F-FDG injection
to same-day pre-resection patient PET/CT was 76 (±8;
range, 64–84) minutes. The time from 18F-FDG injection
to intraoperative gamma probe assessment was 240
(±63; range, 168–304) minutes. The time from 18F-FDG
injection to same-day post-resection limited field of view
patient PET/CT was 487 (±104; range, 331–599) mi-
nutes. The time from 18F-FDG injection to clinical scan-
ner specimen PET/CT of whole surgically excised tissue
specimens was 363 (±60; range, 272–446) minutes. The
time from 18F-FDG injection to specimen gamma well
counting was 591 (±96; range, 420–689) minutes.
Intraoperative gamma probe assessment successfully
identified the 18F-FDG-avid lesion as probe positive (i.e.,
the 18F-FDG-avid lesion/target tissue count rate exceeded
the three-sigma statistical threshold criteria) in 12/13 pa-
tients that were probed. Clinical scanner specimen PET/
CT imaging of whole surgically excised tissue specimens
verified 18F-FDG avidity within the sampled tissue from
all 10 cases that were scanned. Same-day post-resection
limited field of view patient PET/CT imaging verified suc-
cessful removal of the intended 18F-FDG-avid lesions in
all 8 patients that were scanned.
Histopathologic evaluation confirmed lymphoma in
12/13 patients and benign disease (i.e., florid follicular
hyperplasia) in 1/13 patients.
A representative example of a same-day pre-resection
patient PET/CT scan and of a same-day post-resection
patient PET/CT scan are shown in Figure 1 and of speci-
men PET/CT imaging of whole surgically excised tissue
specimens is shown in Figure 2 for a specific case of
histopathology-proven angioimmunoblastic T-cell lymph-
oma that originally presented as a non-palpable, 18F-FDG
Table 1 Variables related to multimodal imaging and detection approach to 18F-FDG-directed surgery
Variable Mean value (± SD; range)
Same-day 18F-FDG injection dose 14.8 (±2.4; 12.5-20.6) millicuries; or
548 (±89; 463–762) megabecquerels
Time from 18F-FDG injection to same-day pre-resection patient PET/CT 76 (±8; 64–84) minutes
Time from 18F-FDG injection to intraoperative gamma probe assessment 240 (±63; 168–304) minutes
Time from 18F-FDG injection to same-day post-resection limited field of view patient PET/CT 487 (±104; 331–599) minutes
Time from 18F-FDG injection to clinical scanner specimen PET/CT of whole surgically excised tissue specimens 363 (±60; 272–446) minutes
Time from 18F-FDG injection to specimen gamma well counting 591 (±96; 420–689) minutes
All variables are expressed as mean value (± standard deviation; range).
Abbreviations: 18F-FDG 18F-fluorodeoxyglucose, PET/CT positron emission tomography/computed tomography, SD standard deviation.
Povoski et al. BMC Cancer  (2015) 15:378 Page 4 of 8avid lesion within the right inguinal/groin region that was
seen on a prior diagnostic patient PET/CT scan in a pa-
tient with a remote history of lymphoma.
Discussion
For lymphoma patients, it is well recognized that 18F-FDG
PET/CT imaging, in contrast to conventional anatomic
imaging modalities (i.e., computed tomography, ultrason-
ography, or magnetic resonance imaging), allows for
improved initial staging, treatment monitoring during
therapy, restaging after completion of therapy, and detec-
tion of recurrent disease in the absence of any notablyFigure 1 Patient imaging. Panel A: Same-day pre-resection whole body p
showing an isolated 18F-FDG-avid lymph node (seen within the region of t
region which was not palpable on clinical examination; and Panel B: Same
(i.e., fused PET/CT images and PET images) showing successful removal of
with residual air in the excision bed (seen within the region of the yellow cclinical and/or biochemical disease manifestations [1-13].
Along similar lines, 18F-FDG PET/CT imaging allows for
the recognition of a lesser degree of disease burden than is
detectable on conventional anatomic imaging modalities,
thus creating a situation in which patients with suspected
new or suspected recurrent lymphoma will less frequently
present with palpable adenopathy on clinical examination.
Surgical biopsy continues to represent the principal diag-
nostic pathway by which a definitive tissue diagnosis is
confirmed in patients with suspected new or suspected
recurrent lymphoma [14]. With the improved detection
of more limited disease burden by 18F-FDG PET/CTatient PET/CT scan images (i.e., fused PET/CT images and PET images)
he yellow circle on the fused axial PET/CT image) in the right inguinal
-day post-resection limited field of view patient PET/CT scan images
the intended 18F-FDG-avid lymph node in the right inguinal region
ircle on the fused axial PET/CT image).
Figure 2 Ex vivo specimen imaging. Panel A: Digital specimen
photograph of the ex vivo tissue specimens, for which the specimen
on the right-hand side histologically was confirmed to contain
angioimmunoblastic T-cell lymphoma, and for which the specimen
on the left side represented normal adjacent fatty tissue; and
Panel B: Maximum intensity projection (MIP) PET image of whole
surgically excised tissue specimens, demonstrating 18F-FDG avidity
within the specimen on the right-hand side, corresponding to the
histopathology-proven lymphoma, and demonstrating no 18F-FDG
avidity within the specimen on the left-hand side.; and Panel C: 3D
CT volume rendering with PET overlay image of whole surgically
excised tissue specimens, demonstrating 18F-FDG avidity within
the specimen on the right-hand side, corresponding to the
histopathology-proven lymphoma.
Povoski et al. BMC Cancer  (2015) 15:378 Page 5 of 8imaging, which is more frequently associated with an in-
ability to appreciate palpable adenopathy on clinical exam-
ination, the surgeon’s ability to successfully target the
appropriate anatomical site of diagnostic tissue sampling
for confirmation of the correct tissue diagnosis is made
more challenging. Therefore, utilizing such innovative
methodologies as a multimodal 18F-FDG-directed lymph
node surgical excisional biopsy approach for guiding ap-
propriate diagnostic tissue sampling of lymph nodes de-
tected as 18F-FDG-avid lesions on diagnostic whole-body
18F-FDG PET/CT imaging can help the surgeon to
maximize the likelihood of success in establishing the cor-
rect tissue diagnosis. Likewise, such methodologies havethe potential for decreasing the degree of invasiveness as
well as the degree of tissue disruption and tissue removal
necessary for accomplishing successful tissue targeting.
Although we fully recognize that the current retro-
spective data analysis is based upon only 13 patients, the
cases presented herein demonstrate that a multimodal
18F-FDG-directed lymph node surgical excisional biopsy
approach for suspected lymphoma is technically feasible
for guiding appropriate diagnostic tissue sampling of
lymph nodes seen as 18F-FDG-avid lesions on diagnostic
18F-FDG PET/CT imaging, especially when such 18F-FDG-
avid lesions are not easily appreciable as palpable adenopa-
thy on clinical examination. Likewise, the conceptualization
of this approach is well illustrated by the case presented in
Figures 1 and 2. It is our belief that such a strategy can be
best maximized when a multimodal imaging and detection
approach is utilized involving perioperative patient and
ex vivo surgical specimen 18F-FDG PET/CT imaging in
combination with intraoperative 18F-FDG gamma probe
detection. This line of reasoning has been validated by our
group for a variety of disease-type-specific solid malignan-
cies [16-18,33,35,36,38-41,43,44,46,47,52,61,69].
Along similar lines, three other groups of investigators
have also previously described the successful utilization of
commercially-available intraoperative hand-held gamma
probe systems for 18F-FDG-directed lymph node surgical
excisional biopsy in patients with suspected or docu-
mented lymphoma [27,31,50,67]. Gulec et al. described
this technique in four patients in one report from 2006
[27] and in six patients in another report from 2007 [31].
Molina et al. described this technique in three patients in
their report from 2009 [50]. Vos et al. described this tech-
nique in one patient in their report from 2012 [67]. How-
ever, none of these three other groups of investigators
utilized perioperative patient and ex vivo surgical speci-
men 18F-FDG PET/CT imaging at the time of intraopera-
tive 18F-FDG gamma probe detection, thus falling short of
incorporating a multimodal approach to this sometimes
challenging diagnostic dilemma.
The ability to successfully perform an 18F-FDG-di-
rected lymph node surgical excisional biopsy procedure
for suspected lymphoma is highly dependent upon the
commercially-available intraoperative hand-held gamma
probe that is used during such a surgical case. The most
important performance parameters related to any given
gamma detection probe system are generally thought to
be: (1) overall sensitivity (i.e., efficiency); (2) spatial se-
lectivity (i.e., radial sensitivity distribution); (3) spatial
resolution (i.e., lateral sensitivity distribution); (4) energy
resolution (i.e., spectral discrimination); and (5) contrast
[46]. The most widely utilized commercially-available
intraoperative hand-held gamma probes are generally
designed for detecting radioisotopes of gamma-ray ener-
gies in the low-energy emission (0 keV to 150 keV) range
Povoski et al. BMC Cancer  (2015) 15:378 Page 6 of 8and medium-energy emission (150 keV to 400 keV) range,
thus allowing successful detection of radioisotopes such
as: (1) technetium-99 m (99mTc; 140 and 142 KeV; most
commonly used for sentinel lymph node biopsy proce-
dures and parathyroid surgery); (2) indium-111 (111In; 171
and 247 KeV; used with octreotide to detect neuroendo-
crine tumors); (3) iodine-123 (123I; 159 KeV; used with
metaiodobenzylguanidine to detect neuroblastomas and
pheochromocytomas); and (4) iodine-125 (125I; 35 KeV;
previously used with anti-TAG-72 monoclonal antibodies
and anti-CEA monoclonal antibodies during radioimmu-
noguided surgery) [46,70].
However, most commercially-available intraoperative
hand-held gamma probes are not specifically designed to
directly or indirectly detect the resultant 511 KeV
gamma emissions following positron annihilation eman-
ating from higher energy gamma photon emitting/posi-
tron emitting radionuclides such as fluorine-18 (18F) or
iodine-124 (124I) [46,70]. Resultantly, there has been a
recent appearance of commercially-available intraoperative
hand-held gamma probes that are specifically intended for
attempting to detect 511 KeV gamma emissions from
higher energy gamma photon emitting/positron emitting
radionuclides. These commercially-available intraoperative
hand-held gamma probes have generally been designated
as “PET” probes. The overall weight and physical size of
any typical “PET” probe is generally a function of the de-
gree of physical side shielding/collimation necessary to
theoretically block adjacent background radiation, to limit
the field of view, and to collimate the head of the probe,
with the intention of limiting the area of tissue contribut-
ing to the probe count rate and of providing better spatial
resolution between areas of tissue of differing radioactivity
levels [46,70,78]. Attempts at improving the current
“PET” probe design by further increasing physical side
shielding/collimation or by increasing crystal diameter/
thickness to capture a higher percentage of 511 KeV
gamma emissions would only result in a “PET” probe con-
figuration prohibitively large in physical size, heavy in
weight, and which would be much more costly [46,70,78],
thus representing significant obstacles to applying the cur-
rently commercially-available “PET” probes to the detec-
tion of 18F-FDG-avid tissues.
In order to attempt to bypass these physical barriers re-
lated to the degree of physical side shielding/collimation
or crystal diameter/thickness in designing intraoperative
hand-held gamma probes that are specifically intended for
attempting to detect 511 KeV gamma emissions from
higher energy gamma photon emitting/positron emitting
radionuclides, engineering efforts have moved toward
other directions for the adaptation of more novel “PET”
probe designs that do not rely upon increasing physical
side shielding/collimation or increasing crystal diameter/
thickness. Examples of such alternative design conceptsthat can be adapted to “PET” probe design are secondary
K-alpha x-ray fluorescence [70,78], active electronic colli-
mation [28,54,58,60,67,79-81], and other crystal geometry
designs using multiple small crystals with specific novel
geometric configurations [82,83] for optimizing back-
ground rejection capabilities. These innovative alterna-
tive design schemas for detecting higher energy gamma
photon emitting/positron emitting radionuclides, some
of which have already been successfully applied to intra-
operative hand-held gamma probe designs, are also the
focus of current pre-clinical research that is actively
looking at developing small platform, portable peri-
operative and intraoperative patient and ex vivo surgical
specimen imaging devices with similar capabilities for
detecting higher energy gamma photon emitting/posi-
tron emitting radionuclides. However, such small plat-
form, portable perioperative and intraoperative patient
and ex vivo surgical specimen imaging devices have not
yet been fully realized or made commercially available
for use in the clinical arena.
Conclusions
A multimodal approach to 18F-FDG-directed lymph node
surgical excisional biopsy for suspected lymphoma is tech-
nically feasible for guiding appropriate diagnostic tissue
sampling of lymph nodes seen as 18F-FDG-avid lesions on
prior diagnostic whole-body 18F-FDG PET/CT imaging.
This multimodal approach can be very helpful to the sur-
geon for accomplishing successful targeting of the appro-
priate anatomical sites (corresponding to 18F-FDG-avid
lesions) for successful diagnostic tissue sampling in con-
firming the correct tissue diagnosis in challenging cases
involving patients with non-palpable suspected new or
suspected recurrent lymphoma.
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